192 related articles for article (PubMed ID: 30087553)
1. HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment.
Shen Y; Li W
Drug Des Devel Ther; 2018; 12():2285-2292. PubMed ID: 30087553
[TBL] [Abstract][Full Text] [Related]
2. Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo.
Tan S; Wang G
Drug Des Devel Ther; 2017; 11():3519-3529. PubMed ID: 29263650
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells.
Maiolino S; Russo A; Pagliara V; Conte C; Ungaro F; Russo G; Quaglia F
J Nanobiotechnology; 2015 Apr; 13():29. PubMed ID: 25888948
[TBL] [Abstract][Full Text] [Related]
4. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
Pang J; Xing H; Sun Y; Feng S; Wang S
Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer.
Zhang W; Xu W; Lan Y; He X; Liu K; Liang Y
Int J Nanomedicine; 2019; 14():5287-5301. PubMed ID: 31406460
[No Abstract] [Full Text] [Related]
6. RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy.
Long Q; Zhu W; Guo L; Pu L
Drug Des Devel Ther; 2020; 14():5747-5756. PubMed ID: 33408463
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation.
Qu N; Sun Y; Li Y; Hao F; Qiu P; Teng L; Xie J; Gao Y
Biomed Eng Online; 2019 Jan; 18(1):11. PubMed ID: 30704488
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma.
Kabary DM; Helmy MW; Elkhodairy KA; Fang JY; Elzoghby AO
Colloids Surf B Biointerfaces; 2018 Sep; 169():183-194. PubMed ID: 29775813
[TBL] [Abstract][Full Text] [Related]
9. Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation.
Zhou X; Tao H; Shi KH
Drug Des Devel Ther; 2018; 12():1-8. PubMed ID: 29296076
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticulation improves bioavailability of Erlotinib.
Yang KM; Shin IC; Park JW; Kim KS; Kim DK; Park K; Kim K
Drug Dev Ind Pharm; 2017 Sep; 43(9):1557-1565. PubMed ID: 28554216
[TBL] [Abstract][Full Text] [Related]
11. Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo/herbal therapy of lung cancer.
Elgohary MM; Helmy MW; Mortada SM; Elzoghby AO
Nanomedicine (Lond); 2018 Sep; 13(17):2221-2224. PubMed ID: 30265215
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting.
Song S; Qi H; Xu J; Guo P; Chen F; Li F; Yang X; Sheng N; Wu Y; Pan W
Pharm Res; 2014 Nov; 31(11):2988-3005. PubMed ID: 24842660
[TBL] [Abstract][Full Text] [Related]
14. A facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers.
Parashar P; Tripathi CB; Arya M; Kanoujia J; Singh M; Yadav A; Saraf SA
Drug Deliv Transl Res; 2019 Feb; 9(1):37-52. PubMed ID: 30178279
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-modified liposomal honokiol nanocarrier: Enhance anti-metastasis and antitumor efficacy against breast cancer.
Wang J; Liu D; Guan S; Zhu W; Fan L; Zhang Q; Cai D
Carbohydr Polym; 2020 May; 235():115981. PubMed ID: 32122511
[TBL] [Abstract][Full Text] [Related]
16. Design and evaluation of albumin nanoparticles for the delivery of a novel β-tubulin polymerization inhibitor.
Spada A; Emami J; Sanaee F; Aminpour M; Paiva IM; Tuszynski J; Lavasanifar A
J Pharm Pharm Sci; 2021; 24():344-362. PubMed ID: 34224665
[TBL] [Abstract][Full Text] [Related]
17. Pursuing for the better lung cancer therapy effect: Comparison of two different kinds of hyaluronic acid and nitroimidazole co-decorated nanomedicines.
Chen G; Zhang Y; Deng H; Tang Z; Mao J; Wang L
Biomed Pharmacother; 2020 May; 125():109988. PubMed ID: 32059173
[TBL] [Abstract][Full Text] [Related]
18. A comparative and systematic approach to desolvation and self-assembly methods for synthesis of piperine-loaded human serum albumin nanoparticles.
Abolhassani H; Shojaosadati SA
Colloids Surf B Biointerfaces; 2019 Dec; 184():110534. PubMed ID: 31627104
[TBL] [Abstract][Full Text] [Related]
19. The roles of short and long chain fatty acids on physicochemical properties and improved cancer targeting of albumin-based fattigation-platform nanoparticles containing doxorubicin.
Park C; Meghani N; Amin H; Tran PH; Tran TT; Nguyen VH; Lee BJ
Int J Pharm; 2019 Jun; 564():124-135. PubMed ID: 30991133
[TBL] [Abstract][Full Text] [Related]
20. Folate-conjugated human serum albumin-encapsulated resveratrol nanoparticles: preparation, characterization, bioavailability and targeting of liver tumors.
Lian B; Wu M; Feng Z; Deng Y; Zhong C; Zhao X
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):154-165. PubMed ID: 30686050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
